<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564613</url>
  </required_header>
  <id_info>
    <org_study_id>208759</org_study_id>
    <nct_id>NCT03564613</nct_id>
  </id_info>
  <brief_title>Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women</brief_title>
  <official_title>DOLOMITE NEAT ID Network Study: A Prospective, Multi-site Observational Study to Define the Safety and Effectiveness of Dolutegravir Use in HIV Positive Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of DTG use in HIV
      positive pregnant women. This is a 3-year multi-site prospective observational study.
      Approximately, 250 HIV positive pregnant women from potential European AIDS Treatment Network
      (NEAT ID) sites across Europe will be enrolled. The enrollment period will be over 2 years
      with a follow-up period of 1 year for outcomes. The data collected will be that obtained
      during routine standard of care assessments; and the subjects will not undergo any
      interventional study procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">April 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of female subjects with spontaneous abortion</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Spontaneous abortion is defined as death of a fetus or expulsion of the products of conception before 22 weeks gestation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of female subjects with induced abortion</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Induced abortion is defined as voluntary termination of pregnancy before 22 weeks gestation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of female subjects giving still births</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Still birth is defined as the death of a fetus occurring at 22 weeks of gestation or more, or for situations in which the gestational age is unavailable, a fetus weighing at least 500 grams.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of female subjects with multiple births</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of female subjects giving multiple births will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of female subjects with type of deliveries</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The different type of deliveries will be summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal viral load (VL) at delivery</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The maternal viral load at the time of delivery will be summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infants with birth defects</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Birth defects will be classified according to World Health Organization's International Classification of Diseases, Tenth Revision.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gestational age</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of females with birth collected data for gestational age as a measure of birth defects will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Birth weight</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of females with birth collected data for birth weight as a measure of birth defects will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of female subjects giving premature births</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Premature birth is defined as birth of live infant at &lt;32 weeks gestation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of female subjects giving live births</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of female subjects giving live births will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infants with low birth weight</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Low birth weight is defined as birth weight of &lt;2500 grams.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appearance, Pulse, Grimace, Activity, Respiration (APGAR) score in infants</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>APGAR score in infants as a measure of birth defects will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV status of Infants</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Infant's HIV status as a measure of birth defects will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of female subjects with drug related Adverse Events and Serious Adverse Events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of females with all drug related Adverse Events and Serious Adverse Events will be reported. These will be categorized by trimester of initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of DTG discontinuation in pregnant women</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of pregnant females with discontinuation of DTG will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who discontinued DTG</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Reasons for DTG discontinuation will be summarized. Number of participants who discontinued DTG will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with VL at discontinuation</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>VL at discontinuation will be summarized to assess suppression. Number of participants with VL at discontinuation will be reported.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV positive pregnant women</arm_group_label>
    <description>Data from approximately 250 HIV positive pregnant women with exposure to DTG from potential investigational sites across Europe will be included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG</intervention_name>
    <description>Subjects with DTG exposure during any trimester will be included</description>
    <arm_group_label>HIV positive pregnant women</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately, 250 HIV positive pregnant women having exposure to DTG from potential NEAT
        ID investigational sites across Europe will be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive pregnant women aged 18 years and over on DTG

          -  With no maternal or birth outcomes yet

          -  Subjects are able and willing to provide written informed consent and comply with any
             safety reporting requirements.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>HIV positive pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marta Guti√©rrez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Dolutegravir</keyword>
  <keyword>Europe</keyword>
  <keyword>NEAT ID</keyword>
  <keyword>pregnancy</keyword>
  <keyword>Safety</keyword>
  <keyword>Antiretroviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request Site</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

